Table 2: Phase III randomized, controlled trials investigating continuation maintenance therapy.

Trial	Induction chemotherapy	Maintenance regimen	Median PFS	Median OS
CECOG, Brodowicz et al. Lung Cancer 2006 [22]	Cisplatin + gemcitabine × 4 cycles	Gemcitabine vs. BSC	3.6 vs. 2.0 months, p < 0.001	13.0 vs. 11.0 months, p = 0.195
Belani et al. 2010 [23]	Carboplatin + gemcitabine × 4 cycles	Gemcitabine vs. BSC	3.9 vs. 3.8 months, p = 0.58	8.0 vs. 9.3 months, p = 0.84
Perol et al. JCO 2012 [16]	Cisplatin + gemcitabine × 4 cycles	Gemcitabine vs. placebo (vs. erlotinib)	3.8 vs. 1.9 months, p < 0.001	12.1 vs. 10.8 months, p = 0.3867
PARAMOUNT, Paz-Ares et al. Lancet Oncol 2012 [17,20]	Cisplatin + pemetrexed× 4 cycles	Pemetrexed vs. placebo	4.1 vs. 2.8 months, p < 0.0001	13.9 vs. 11.0 months, p = 0.0195
AVAPERL, Barlesi et al. JCO 2013 [18,21]	Cisplatin + pemetrexed + bevacizumab × 4 cycles	Bevacizumab + pemetrexed vs. bevacizumab	7.4 vs. 3.7 months, p < 0.0001	17.1 vs. 13.2 months, p = 0.29
Point Break, Patel et al. JCO 2013 [19]	Carboplatin + bevacizumab + (pemetrexed vs. paclitaxel) × 4 cycles	Maintenance of non-carbo therapy: Bev + (pemetrexed vs. paclitaxel)	6.0 vs. 5.6 months, p = 0.012	12.6 vs. 13.4 months, p = 0.949